|
Post by JHam on Sept 17, 2018 21:47:25 GMT
Thanks for the response. Yeah, but if ATHN acquires CATS what would they do with it? Would they block other insurance companies from having access to InTrak, monopolizing the program? Would they continue what CATS has started, allowing the competition to save money and benefit? It doesn’t really fit an insurance company’s regular business model. But yeah, who knows. If someone buys it out for $2.5B, I’ll take it. It was just some thoughts, ATHN is not insurance, it’s a cloud based data management for large healthcare systems for billing and medical histories, CATS would be folded in as part of the service. Or maybe not? No appreciate it. That’s good to know. I was thinking ATHN was just a typical insurance company (tough keeping track when you live in a country that has a nationalized system ). Seeing that Terren Peizer owns over 60% of the float I guess we don’t have to worry about a hostile takeover.
|
|
|
Post by selluwud on Sept 18, 2018 13:57:50 GMT
Not wanting to jinx a good thing, but another good day?
|
|
|
Post by vzveteran on Sept 18, 2018 15:29:06 GMT
Just broke 14....been waiting for a pullback....Something in the pipe we don't know about yet?
|
|
|
Post by lcd on Sept 18, 2018 17:41:00 GMT
While I am just sitting back and enjoying the pps run up, I do have a question for the board about the long term viability of Catasys. If the OnTrak program is as successful as hoped, what is to stop any insurer or provider from replicating the program themselves? Catasys advertises their solution in three steps (https://catasys.com/solution.html);
1. predictive modeling - This is a differentiator if insurers agree that Catasys's data analytics are superior to their own abilities. I expect Catasys to continue to build on their current models (they are currently advertising to hire a Senior Data Scientist) and leverage them to penetrate into new markets. 2. engagement - Catasys says they have an innovative approach but I struggle to imagine how this can be a real differentiator, nor can I figure out how they can block competition through patents or IP for it. It also sounds resource intensive so I don't think this is a profitable part of the company, nor will it be because as the number of patients increase so do the engagement resources needed. 3. treatment - OnTrak "integrates medical assessments, skills-based therapy and care coaching." I don't claim to understand what a "Proprietary OnTrak manualized psychosocial treatment program" is but can it really be so revolutionary or patentable that no one else can replicate it?
My concerns about the exclusivity of OnTrak are longer term concerns because right now all the big insurers are buying into what Catasys is offering, but without understanding more details (than what I can pull from corporate presentations) about OnTrak, I struggle to see how the treatment program's success can be proprietary in the future. I wonder if Catasys's predictive modeling is as much of the driver in growth as OnTrak?
|
|
|
Post by JHam on Sept 19, 2018 3:27:19 GMT
While I am just sitting back and enjoying the pps run up, I do have a question for the board about the long term viability of Catasys. If the OnTrak program is as successful as hoped, what is to stop any insurer or provider from replicating the program themselves? Catasys advertises their solution in three steps (https://catasys.com/solution.html); 1. predictive modeling - This is a differentiator if insurers agree that Catasys's data analytics are superior to their own abilities. I expect Catasys to continue to build on their current models (they are currently advertising to hire a Senior Data Scientist) and leverage them to penetrate into new markets. 2. engagement - Catasys says they have an innovative approach but I struggle to imagine how this can be a real differentiator, nor can I figure out how they can block competition through patents or IP for it. It also sounds resource intensive so I don't think this is a profitable part of the company, nor will it be because as the number of patients increase so do the engagement resources needed. 3. treatment - OnTrak "integrates medical assessments, skills-based therapy and care coaching." I don't claim to understand what a "Proprietary OnTrak manualized psychosocial treatment program" is but can it really be so revolutionary or patentable that no one else can replicate it? My concerns about the exclusivity of OnTrak are longer term concerns because right now all the big insurers are buying into what Catasys is offering, but without understanding more details (than what I can pull from corporate presentations) about OnTrak, I struggle to see how the treatment program's success can be proprietary in the future. I wonder if Catasys's predictive modeling is as much of the driver in growth as OnTrak? Did you by any chance listen to Terren speak at Canaccord? He goes into detail to address your exact question. It would be best to hear it from the horse’s mouth, but in summary, he explains how and why it took 14 years for them to develop InTrak and that no one else is crazy enough to do the same. Thus there is no competition.
|
|
|
Post by JHam on Sept 19, 2018 4:37:12 GMT
While I am just sitting back and enjoying the pps run up, I do have a question for the board about the long term viability of Catasys. If the OnTrak program is as successful as hoped, what is to stop any insurer or provider from replicating the program themselves? Catasys advertises their solution in three steps (https://catasys.com/solution.html); 1. predictive modeling - This is a differentiator if insurers agree that Catasys's data analytics are superior to their own abilities. I expect Catasys to continue to build on their current models (they are currently advertising to hire a Senior Data Scientist) and leverage them to penetrate into new markets. 2. engagement - Catasys says they have an innovative approach but I struggle to imagine how this can be a real differentiator, nor can I figure out how they can block competition through patents or IP for it. It also sounds resource intensive so I don't think this is a profitable part of the company, nor will it be because as the number of patients increase so do the engagement resources needed. 3. treatment - OnTrak "integrates medical assessments, skills-based therapy and care coaching." I don't claim to understand what a "Proprietary OnTrak manualized psychosocial treatment program" is but can it really be so revolutionary or patentable that no one else can replicate it? My concerns about the exclusivity of OnTrak are longer term concerns because right now all the big insurers are buying into what Catasys is offering, but without understanding more details (than what I can pull from corporate presentations) about OnTrak, I struggle to see how the treatment program's success can be proprietary in the future. I wonder if Catasys's predictive modeling is as much of the driver in growth as OnTrak? By the way, I am not trying to brush off your concerns. I think they are valid. I was just trying explain what Terren said.
|
|
|
Post by JHam on Sept 19, 2018 11:27:59 GMT
Great to see another huge volume day yesterday. I like this daily pattern of big gains, consolidation, settling at a new level up. I won't complain if it continues
|
|
|
Post by lcd on Sept 19, 2018 18:16:34 GMT
Did you by any chance listen to Terren speak at Canaccord? He goes into detail to address your exact question. It would be best to hear it from the horse’s mouth, but in summary, he explains how and why it took 14 years for them to develop InTrak and that no one else is crazy enough to do the same. Thus there is no competition. JHam, I did go back and listen to the Canaccord presentation again and while I think it was a great presentation and gives me great confidence in this company over the next year or more, I still can't grasp what could be so unique about OnTrak that it can't be replicated, especially since it sounds like the medical professionals implementing it are contractors and not OnTrak staff. I suppose it is my ignorance of treatment programs and all that goes into making them successful.
After listening to the presentation, I bought a small additional lot of shares for $12.94 so my average is creeping up towards $9 now.
|
|
|
Post by selluwud on Sept 21, 2018 18:41:45 GMT
CATS has been giving it back the last couple of days. I almost sold 2 days ago and was going to re-invest in CRSP after their offering details were revealed which was out today. Still sitting tight though.
|
|
|
Post by vzveteran on Sept 21, 2018 20:05:14 GMT
I bailed,sold my position, locked in 39% gain.....took the profit while I can...small bites are fine for me these days...
|
|
|
Post by JHam on Sept 22, 2018 2:26:19 GMT
I bailed,sold my position, locked in 39% gain.....took the profit while I can...small bites are fine for me these days... Well done! I did pretty well with the "small bites"-strategy the past few months with RDHL and PRTK, though they actually ended up being pretty solid profits. So with CATS I don't feel the urge to sell and am happy to hold this until it hits my target sell price.
|
|
|
Post by selluwud on Sept 24, 2018 14:46:13 GMT
Sold today at 50% and reloaded in CRSP now that they've announced their raise price. It's a hit or miss gamble. FDA clearance and zoom, dead air.....back down.
|
|
|
Post by lcd on Sept 24, 2018 15:34:11 GMT
Congrats to those who locked into profits. Like JHam, I am holding (and might even add).
|
|
|
Post by JHam on Sept 24, 2018 15:53:25 GMT
Sold today at 50% and reloaded in CRSP now that they've announced their raise price. It's a hit or miss gamble. FDA clearance and zoom, dead air.....back down. Congrats on the big trade and good luck with CRSP!
|
|
|
Post by JHam on Sept 26, 2018 11:12:59 GMT
Yesterday's news: www.businesswire.com/news/home/20180925005306/en/Catasys Announces Expansion of OnTrak-A Solution to Florida and Georgia with Leading National Health PlanNational Plan Expands OnTrak-A into 12th and 13th States
September 25, 2018 08:30 AM Eastern Daylight Time
LOS ANGELES--(BUSINESS WIRE)--Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that it has expanded its OnTrak-A solution into Florida and Georgia with one of the nation’s leading health plans. This follows OnTrak-A’s expansion into Iowa and Nebraska earlier this month.
Eligible commercial and Medicare Advantage plan members in Florida and Georgia are now able to participate in OnTrak-A, an integrated 52-week program that identifies, engages and treats members with unaddressed behavioral health conditions that impact co-morbid medical conditions, such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure, resulting in high medical costs. Catasys has a unique ability to engage these care avoidant members, improving their health while reducing healthcare costs.
Rick Anderson, President and Chief Operating Officer of Catasys, stated, “We are pleased to see this health plan partner continue to expand their deployment of the OnTrak program, validating the results our program has yielded—their members’ improved quality of life and significantly lower healthcare costs. Our goal is to engage and effectively treat as many members as possible, and we look forward to our continued partnership with this national health plan.”
|
|
|
Post by magnus123 on Sept 26, 2018 12:36:01 GMT
Nice news. Additionaly, Canaccord raised their price targed today from $12 to $15.
|
|
|
Post by JHam on Sept 26, 2018 12:50:17 GMT
Nice news. Additionaly, Canaccord raised their price targed today from $12 to $15. I saw that. I hope they'll have to move it up again soon
|
|
|
Post by JHam on Sept 28, 2018 20:42:58 GMT
Catasys Calls for Improved Engagement to Solve for the Crisis of Untreated Anxiety Disorders in Published Paper Authored by Chief Medical Officer
September 27, 2018
LOS ANGELES--(BUSINESS WIRE)--
Catasys, Inc. (CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that a paper authored by its Senior Vice President and Chief Medical Officer Omar S. Manejwala titled “Anxiety Disorders: Scope and Clinical Considerations” has been published in the peer-reviewed Journal of Managed Care Medicine.
In the paper, Dr. Manejwala writes, “Despite the widespread availability of multiple treatments for anxiety disorders and substantial morbidity of untreated illness, the vast majority of individuals with anxiety disorders remain untreated. A National Comorbidity Study Replication found that only 36.9 percent of individuals with anxiety disorder received any treatment in the past 12 months and delay among those who eventually make treatment contact ranges from nine to 23 years. Fewer than one-third of the cases received minimally adequate care.”
Commenting on the paper, Dr. Manejwala stated, “Anxiety disorders are the most common psychiatric conditions—and they are responsible for over $20 billion in annual costs related to worsening medical conditions. Effective treatments exist but engagement remains poor, so most people cannot get the care they so desperately need to recover. Catasys’ mission is to solve for this needless suffering by uniquely engaging people in a program that produces durable behavior change, significantly improving quality of life while reducing healthcare costs.”
Catasys identifies, engages and treats health plan members with unaddressed behavioral conditions such as anxiety that worsen their chronic medical diseases. Today these members, who represent 1% to 3% of the health plan population, drive an anticipated average of 20% to 30% of all medical expenditures, and that number appears to be growing over time. These care avoidant members are identified through predictive analytics, engaged through multi-modal outreach and relationship-building, and enrolled in the OnTrak program. OnTrak is an integrated, 52-week program that delivers AI fingerprinted, evidence-based treatments. The result is better health and improved quality of life for the member, and an approximately 50% reduction in paid claims from the year prior to enrollment that is durable over a two-year period.
|
|
|
Post by vzveteran on Oct 1, 2018 19:50:09 GMT
10% drop......bought a small position again....I can't see a continued downturn...gotta be alot of bagholders at $14.50 no?
|
|
|
Post by lcd on Oct 1, 2018 20:10:57 GMT
I saw today as a buying opportunity so I sold some oil stock and added about 25% more CATS shares at $11.26 right before the bell. Hope the late afternoon sell starts to correct tomorrow.
|
|